Avenue therapeutics announces completion of enrollment in phase 1b/2a clinical trial of aj201 for the treatment of spinal and bulbar muscular atrophy (kennedy's disease)

- topline data remains on track for second quarter of 2024 - miami, jan. 02, 2024 (globe newswire) -- avenue therapeutics, inc. (nasdaq: atxi) (“avenue” or the “company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that all patients have been enrolled in the phase 1b/2a clinical trial of aj201 for the treatment of spinal and bulbar muscular atrophy (“sbma”), also known as kennedy's disease. aj201 is currently the lead drug candidate in the clinic for sbma, and topline data are anticipated in the second quarter of 2024.
ATXI Ratings Summary
ATXI Quant Ranking